ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2015
Improved anticancer delivery of paclitaxel by albumin surface modification of PLGA nanoparticles.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 53 citations in OpenAlex.
- Co-delivery of SN38 and rapamycin albumin bound nanoparticles against breast Cancer.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Article
- Antibacterial Activity and Cytotoxicity Screening of Acyldepsipeptide-1 Analogues Conjugated to Silver/Indium/Sulphide Quantum Dots.Antibiotics (Basel, Switzerland) · 2024Article
- Cyclodextrin Nanosponges: A Revolutionary Drug Delivery Strategy.Pharmaceutical nanotechnology · 2024Review
- Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2023Article
- PLGA's Plight and the Role of Stealth Surface Modification Strategies in Its Use for Intravenous Particulate Drug Delivery.Advanced healthcare materials · 2022Review
- Review
- Article
- Post-process optimization of 3D printed poly(lactic-co-glycolic acid) dental implant scaffold for enhanced structure and mechanical properties: effects of sonication duration and power.Journal of materials science. Materials in medicine · 2021Article
- Cytotoxicity of targeted PLGA nanoparticles: a systematic review.RSC advances · 2021Review
- Article
- S2P peptide-conjugated PLGA-Maleimide-PEG nanoparticles containing Imatinib for targeting drug delivery to atherosclerotic plaques.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Article
- Paclitaxel incorporated exosomes derived from glioblastoma cells: comparative study of two loading techniques.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019Article
- Applications of nanoparticles in biomedical imaging.Nanoscale · 2019Review
- Paclitaxel-loaded PLGA microspheres with a novel morphology to facilitate drug delivery and antitumor efficiency.RSC advances · 2018Article
- Tailoring Lipid and Polymeric Nanoparticles as siRNA Carriers towards the Blood-Brain Barrier - from Targeting to Safe Administration.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017Article
- Anti-inflammatory Nanoparticle for Prevention of Atherosclerotic Vascular Diseases.Journal of atherosclerosis and thrombosis · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNanoparticles (NPs) play an important role in anticancer delivery systems. Surface modified NPs with hydrophilic polymers such as human serum albumin (HSA) have long half-life in the blood circulation system.
methodsThe method of modified nanoprecipitation was utilized for encapsulation of paclitaxel (PTX) in poly (lactic-co-glycolic acid) (PLGA). Para-maleimide benzoic hydrazide was conjugated to PLGA for the surface modifications of PLGA NPs, and then HSA was attached on the surface of prepared NPs by maleimide attachment to thiol groups (cysteines) of albumin. The application of HSA provides for the longer blood circulation of stealth NPs due to their escape from reticuloendothelial system (RES). Then the physicochemical properties of NPs like surface morphology, size, zeta potential, and in-vitro drug release were analyzed.
resultsThe particle size of NPs ranged from 170 to 190 nm and increased about 20-30 nm after HSA conjugation. The zeta potential was about -6 mV and it decreased further after HSA conjugation. The HSA conjugation in prepared NPs was proved by Fourier transform infrared (FT-IR) spectroscopy, faster degradation of HSA in Differential scanning calorimetry (DSC) characterization, and other evidences such as the increasing in size and the decreasing in zeta potential. The PTX released in a biphasic mode for all colloidal suspensions. A sustained release profile for approximately 33 days was detected after a burst effect of the loaded drug. The in vitro cytotoxicity evaluation also indicated that the HSA NPs are more cytotoxic than plain NPs.
conclusionsHSA decoration of PLGA NPs may be a suitable method for longer blood circulation of NPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.